Coxib-inhibition of Duodenal Polyp Growth in FAP

Phase 3TerminatedNCT00844727

Oslo University Hospital38 enrolled

Overview

Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Duodenal Polyposis

Interventions

RofecoxibDRUG

placeboDRUG

placebo pills

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * FAP patient with previous colectomy and confirmed polyposis Exclusion Criteria: * Pregnancy * Malignancy * NSAID hypersensitivity

Locations (1)

Dept of Medicine, Rikshospitalet

Oslo, Oslo County, Norway

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.